Subscribe To

Price Alert Latest News Economic Calendar News

CMRX / Chimerix stock surges after deal to sell smallpox treatment Tembexa for up to $337.5 million, plus royalties

Shares of Chimerix Inc. CMRX, +3.41% shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. Read More

Demo Live Account See Partner Details

Content Topics

Chimerix

Stock

Surges

After

Deal

Sell

Smallpox

Treatment

Tembexa

337 5

Million

Royalties

CMRX

Posted: May 16 2022, 06:43

Author Name: Market Watch

CMRX News

By Seeking Alpha
September 8, 2023

Chimerix: Dangerous Road, Thesis Intact

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out i

By Seeking Alpha
August 5, 2023

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of S

By Seeking Alpha
June 6, 2023

Chimerix: A High-Risk 'Lottery Ticket'

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development,

By Proactive Investors
May 25, 2023

Chimerix's trial treating pediatric brain tumors has a 'relatively high' chance of success

The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according

By Seeking Alpha
May 6, 2023

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strat

By Seeking Alpha
March 2, 2023

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strat

By Zacks Investment Research
November 29, 2022

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

By Seeking Alpha
November 4, 2022

Chimerix, Inc. (CMRX) Q3 2022 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-St

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.